PC-3,
DU145,
MDA-MB-468,
OVCAR-3,
CFPAC-1, and
HCT116 cancer cell lines were purchased from ATCC and used as such as authentication of the cell lines was provided with their purchase from ATCC.
The LNCaP cell line is the parental cell line and the C4-2 and C4-2B are all derivatives of the LNCaP parental cell line. These cell lines were developed by Leland Chung's group (Cedars-Sinai Medical Center, LA, CA) and were obtained from his lab as a generous gift. C4-2B cells were tested for mycoplasma contamination using
MycoAler Mycoplasma Detection Kit from Lonza.
PC-3-luc cells were purchased from Perkin Elmer and periodically tested for mycoplasma contamination using
MycoAler Mycoplasma Detection Kit from Lonza.
All experiments were performed with cells between 10–15 passages.
Saxena R., Yang C., Rao M., Turaga R.C., Garlapati C., Gundala S.R., Myers K., Ghareeb A., Bhattarai S., Kamilinia G., Bristi S., Su D., Gadda G., Rida P.C., Cantuaria G.H, & Aneja R. (2017). Preclinical development of a non-toxic oral formulation of monoethanolamine, a lipid precursor, for prostate cancer treatment. Clinical cancer research : an official journal of the American Association for Cancer Research, 23(14), 3781-3793.